Ribbon Acquisition Corp. (RIBB) · Nov 2, 2026 · Delisting
Nasdaq deficiency — MVLS below $35M for 30 business days; cure deadline April 28, 2027
Ribbon Acquisition’s Nasdaq notice exposes a market-value shortfall, leaving the DRC Medicine SPAC six months to regain compliance.
Ribbon Acquisition is a blank-check SPAC trying to complete its proposed DRC Medicine combination, after extending its transaction deadline to January 16, 2027. Its business is still essentially the deal itself: the company has no operating revenue and has warned of substantial doubt about continuing as a going concern before a combination or liquidation.
The filing adds a real listing problem, not an immediate delisting. Nasdaq says Ribbon’s market value of listed securities stayed below the $35 million requirement for 30 consecutive business days, from September 18 through October 29, 2026, and that the company also failed the alternative equity and earnings tests.
The immediate business impact is limited, but the deadline raises execution pressure around the merger. Trading continues for now, and Ribbon has 180 calendar days—through April 28, 2027—to produce at least $35 million of market value for 10 consecutive business days. 〔0〕 The date falls after the current January 16, 2027 combination deadline, so the notice does not by itself extend the deal timetable; it instead creates a second path to failure if the transaction slips or does not improve the listing metrics.
This is a setback to the SPAC’s already fragile transaction story, though not yet a reversal. The company can cure the deficiency without a financing or reverse split being disclosed in this filing, but it gives no concrete remediation plan beyond monitoring options and offers no assurance of regaining compliance. 〔1〕
Bottom line: Ribbon remains listed today, but the notice makes its path to completing the DRC Medicine deal more operationally constrained. It is a manageable warning rather than a delisting, yet it weakens an already time-limited SPAC setup.
Nasdaq compliance test by April 28, 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!